Wells Fargo
RAPP

Wells Fargo’s Rapport Therapeutics RAPP Stock Holding History

Wells Fargo’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34M Buy
32,171
+21,055
+189% +$774K ﹤0.01% 3910
2026
Q1 		$348K Sell
11,116
-20,993
-65% -$590K ﹤0.01% 4345
2025
Q4 		$974K Buy
32,109
+18,647
+139% +$516K ﹤0.01% 3992
2025
Q3 		$400K Buy
13,462
+2,195
+19% +$39.2K ﹤0.01% 4461
2025
Q2 		$128K Buy
11,267
+2,300
+26% +$24.4K ﹤0.01% 5050
2025
Q1 		$89.9K Buy
8,967
+4,143
+86% +$53.8K ﹤0.01% 5158
2024
Q4 		$85.6K Buy
4,824
+1,352
+39% +$30K ﹤0.01% 5284
2024
Q3 		$71.1K Buy
+3,472
New +$74.6K ﹤0.01% 5201

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Wells Fargo's RAPP Position: Q2 2026 in Review

Wells Fargo increased its Rapport Therapeutics (RAPP) stake by 189% in Q2 2026, buying an estimated $774K and bringing the position to 32,171 shares worth $1.34M. The position accounts for ﹤0.01% of the portfolio, ranked #3910.

Wells Fargo first reported a position in RAPP in Q3 2024 and has held it in 8 quarters since. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Wells Fargo held 32,171 shares of Rapport Therapeutics worth $1.34M as of Q2 2026.
  • Wells Fargo bought 21,055 Rapport Therapeutics shares in Q2 2026, an estimated $774K.
  • Rapport Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3910 holding.
  • Wells Fargo first reported a position in Rapport Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.